HiberCell

Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As "the dormancy company," we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.